我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
6
4 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
2
33.3%
尚未招募
4
66.7%
暂无批准数据
- Kevin Lane, a 67-year-old Bendigo resident diagnosed with metastatic prostate cancer in 2018, has become the first Australian to participate in an international trial of a new drug aimed at delaying chemotherapy. - The clinical trial, conducted at Bendigo Health, represents a significant advancement in regional cancer care, offering patients access to cutting-edge treatments without traveling to metropolitan centers. - Prostate cancer, now the most commonly diagnosed cancer in Australia and the leading new cancer in Bendigo, may see treatment protocols evolve if this experimental therapy successfully improves quality of life for patients with bone metastases.
